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Efficacy and Safety of Guselkumab, an Interleukin-23p  
19–Specific Monoclonal Antibody, Through One Year in 
Biologic-Naive Patients With Psoriatic Arthritis
Iain B. McInnes,1  Proton Rahman,2 Alice B. Gottlieb,3  Elizabeth C. Hsia,4 Alexa P. Kollmeier,5  
Soumya D. Chakravarty,6  Xie L. Xu,5 Ramanand A. Subramanian,7 Prasheen Agarwal,7 Shihong Sheng,7 
Yusang Jiang,8 Bei Zhou,7 Yanli Zhuang,7 Désirée van der Heijde,9 and Philip J. Mease10
Objective. Guselkumab, a human monoclonal antibody specific to interleukin-23p19, demonstrated efficacy and 
safety versus placebo through week 24 of the phase III DISCOVER-2 trial in biologic-naive patients with psoriatic 
arthritis (PsA). Here we report 1-year DISCOVER-2 findings.
Methods. Adults with active PsA (≥5 swollen and ≥5 tender joints; C-reactive protein level ≥0.6 mg/dl) despite 
standard nonbiologic treatment were randomized to receive subcutaneous injections of guselkumab 100 mg every 
4 weeks, guselkumab 100 mg at week 0, week 4 and every 8 weeks thereafter, or placebo with crossover to guselkumab 
100 mg every 4 weeks at week 24. We primarily evaluated clinical efficacy through week 52 by imputing missing data 
(nonresponse for categorical end points; no change/using multiple imputation for continuous end points). Observed 
radiographic scores and adverse events (AEs) were summarized.
Results. Of 739 randomized, treated patients, 93% completed week 52. The proportions of patients in whom 
a ≥20% improvement from baseline in American College of Rheumatology criteria (ACR20) was achieved were 
maintained after week 24, reaching 71% (173 of 245) and 75% (185 of 248) for patients randomized to receive treatment 
every 4 weeks or every 8 weeks, respectively, by week 52. The proportions of patients in whom ACR50/ACR70 and 
skin responses, minimal or very low disease activity, and dactylitis or enthesitis resolution were achieved at week 
24 were also maintained through week 52. Further, low levels of radiographic progression, along with improvements 
in physical function and health-related quality of life, were sustained through week 52 with continued guselkumab 
treatment. Few patients experienced serious infections through week 52, with no evidence of a dosing regimen 
response or increase from weeks 0–24 (4 of 493 [0.8%]) to weeks 24–52 (3 of 493 [0.6%]) among guselkumab-
randomized patients. No patient developed an opportunistic infection or died.
Conclusion. In biologic-naive PsA patients, guselkumab provided sustained improvements across diverse 
manifestations and maintained a favorable risk–benefit profile through week 52.
A video abstract of this article can be found at https://players.brightcove.
net/656326989001/default_default/index.html?videoId=6207835525001.
ClinicalTrials.gov identifier: NCT03158285.
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INTRODUCTION
Psoriatic arthritis (PsA), a heterogenous chronic inflammatory 
disorder, can encompass peripheral arthritis, psoriasis, enthesi-
tis, dactylitis, and axial involvement. Current therapies vary in 
their ability to address the protean manifestations of PsA. Not all 
patients respond to each treatment, and some who experience 
an initial response lose the effect over time (1–3). In the Corrona 
registry, ~30% of tumor necrosis factor inhibitors (TNFi) started 
by PsA patients were discontinued within 1 year, and biologic- 
exposed patients demonstrated lower TNFi drug persistence than 
biologic-naive patients (4). The high proportion (80%) of these 
patients discontinuing the index TNFi because of inadequate effi-
cacy (5) highlights the need to consider other modes of action 
to treat these PsA patients. Guselkumab (Janssen Biotech), a 
fully human monoclonal antibody specific to the p19 subunit of 
interleukin-23 (IL-23), was approved to treat adults with moderate- 
to-severe plaque psoriasis in 2017. More recently, guselkumab 
was the first selective IL-23 inhibitor approved in the US, 
as well as in Canada, Ecuador, and Brazil, to treat active PsA (6).
IL-23, comprising a p19 subunit and a p40 subunit shared 
with IL-12, is an upstream regulatory cytokine that modulates the 
expansion and survival of human CD4+ IL-17–producing Th17 
cells, CD8+ IL-17–producing Tc17 cells, and innate immune cell 
subsets, all of which represent sources of downstream effector 
cytokines (e.g., IL-17A, IL-17F, TNF, and IL-22) known to drive 
inflammatory disease (7–10). Preclinical data suggested that the 
IL-23/Th17 pathway, and overexpression of IL-23 in particular, is a 
key driver of arthritis, psoriasiform lesions, enthesitis, and sacroili-
itis, all features of PsA (11,12).
Guselkumab demonstrated robust benefit in patients 
with moderate-to-severe psoriasis (13–15). The high specificity 
and affinity of guselkumab for the IL-23p19 subunit (16) augured 
the ability of guselkumab to also treat PsA, and clinical data have 
borne that out (17–19). In recent reports of the 24-week placebo- 
controlled portions of 2 pivotal trials of guselkumab in PsA 
(DISCOVER-1 [ClinicalTrials.gov identifier: NCT03162796] and 
DISCOVER-2 [ClinicalTrials.gov identifier: NCT03158285]), gusel-
kumab 100 mg every 4 weeks or every 8 weeks significantly 
improved signs and symptoms of joint and skin disease (18,19), 
and guselkumab 100 mg every 4 weeks significantly inhibited the 
progression of structural damage (19).
Herein we report the results of DISCOVER-2, the larger of 
these pivotal trials, through 52 weeks. Results include 1-year clin-
ical and radiographic data for biologic-naive patients randomized 
to receive guselkumab, and the effects of guselkumab in patients 
randomized to receive placebo followed by guselkumab begin-
ning at week 24.
PATIENTS AND METHODS
Patients. As previously reported, 739 adults with PsA 
were enrolled and treated in DISCOVER-2 (19). Participants had 
active PsA (≥5 tender and ≥5 swollen joints; C-reactive protein 
[CRP] ≥0.6 mg/dl) despite standard nonbiologic treatment 
(disease-modifying antirheumatic drugs [DMARDs], apremilast, or 
nonsteroidal antiinflammatory drugs [NSAIDs]) and were naive 
for biologic agents and JAK inhibitors. Patients provided written 
informed consent.
Study design. This phase III, randomized, double-blind, 
placebo-controlled, 3-arm study was conducted at 118 sites (in 
Bulgaria, the Czech Republic, Estonia, Latvia, Lithuania, Malaysia, 
Poland, Russia, Spain, Taiwan, Turkey, Ukraine, and the US). The 
trial design includes a 6-week screening period (beginning July 
13, 2017), a 100-week treatment phase (placebo-controlled from 
week 0 to week 24 and active treatment from week 24 to week 
100), and 12 weeks of safety follow-up. Data collected through 
week 52 (last visit September 10, 2019) are reported herein.
Participants were randomized 1:1:1 to receive subcuta-
neous injections of guselkumab 100 mg every 4 weeks; gusel-
kumab 100 mg at week 0, week 4, and then every 8 weeks; or 
placebo every 4 weeks until starting guselkumab 100 mg every 
4 weeks at week 24. Central randomization and blinding details 
were previously reported (19). Patients could continue baseline 
use of stable doses of selected nonbiologic DMARDs (limited 
to either methotrexate ≤25 mg/week, sulfasalazine ≤3 gm/day, 
hydroxychloroquine ≤400 mg/day, or leflunomide ≤20 mg/day), 
oral glucocorticoids ≤10 mg/day of prednisone or equivalent dose, 
and NSAIDs or other analgesics up to regionally approved doses.
DISCOVER-2 (ClinicalTrials.gov identifier: NCT03158285) is 
being conducted according to Declaration of Helsinki and Good 
Clinical Practice guidelines. The protocol was approved by gov-
erning ethics bodies.
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Procedures. Study visits were scheduled for screening, 
baseline (week 0), week 2, and week 4, and then every 4 weeks. 
Independent assessors evaluated joints for tenderness (n = 68) 
and swelling (n = 66, excluding hips), enthesitis (Leeds Enthesitis 
Index [LEI]; total score 0–6 as summed for 6 nontender [score 0] 
or tender [score 1] anatomic sites) (20), and dactylitis (Dactylitis 
Severity Score; total score 0–60 as summed for each finger and 
toe, scored on a scale of 0–3, where 0 = no dactylitis, 1 = mild 
dactylitis, 2 = moderate dactylitis, and 3 = severe dactylitis) (21,22). 
Patients reported their pain level (on a 0–10-cm visual analog 
scale [VAS]), global impression of disease activity (0–10-cm VAS), 
and physical function (Health Assessment Questionnaire [HAQ] 
disability index [DI] [0–3 scale]) (23). Investigators completed the 
global assessment of disease activity (0–10-cm VAS), and serum 
CRP level (mg/dl) was determined.
Single radiographs of the hands (posteroanterior) and feet 
(anteroposterior), obtained at week 0 and week 24 (or at discon-
tinuation if before week 24) for the first reading session and at 
week 0, week 24, and week 52 (or at discontinuation if between 
weeks 24 and 52) for the second reading session, were inde-
pendently evaluated by 2 central primary readers, with a third 
reader for adjudication (assignment of readers to primary reader/
adjudicator roles differed between reading sessions; see Sup-
plementary Methods, available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41553/ 
abstract). Readers were blinded with regard to clinical data and 
radiograph ordering when scoring films using the modified Sharp/
van der Heijde score (SHS) for PsA (24).
Investigators assessed the severity of skin disease using the 
Investigator’s Global Assessment of psoriasis (IGA; total score 0–4 
as averaged across induration, erythema, and scaling, graded on 
a scale of 0–4, where 0 = cleared, 1 = minimal, 2 = mild, 3 = moder-
ate, and 4 = severe) (25). The Psoriasis Area and Severity Index 
(PASI; total score 0–72) (26) assessed the extent (percentage 
of body surface area [BSA] affected) and degree of associated 
redness, thickness, and scaling (each graded on a scale of 0–4, 
where 0 = none and 4 = maximum).
The Short Form 36 (SF-36) health survey (27) physical com-
ponent summary (PCS) and mental component summary (MCS) 
scores were used to assess health-related quality of life (HRQoL). 
The presence of suicidal ideation/behavior or nonsuicidal self- 
injurious behavior was surveyed using electronic Columbia-Suicide 
Severity Rating Scale [eC-SSRS] questionnaires (28). Adverse 
events (AEs) and routine hematology and chemistry parameters 
were monitored. Details of guselkumab pharmacokinetic and 
immunogenicity assessments have been reported previously (19).
Outcome measures. Outcome measures assessed 
through week 52 included American College of Rheumatology 
criteria for 20% improvement (ACR20), ACR50, and ACR70 
responses; change from baseline in the Disease Activity Score 
in 28 joints using the CRP; IGA skin response (score 0/1 and 
≥2 grade improvement) and skin response assessed as ≥75%, 
≥90%, or 100% improvement in the PASI (PASI75, PASI90, and 
PASI100, respectively), all among patients with ≥3% BSA with 
psoriasis and IGA ≥2 at baseline; changes from week 0 to week 
2, week 24 to week 52, and week 0 to week 52 in total PsA- 
modified  SHS score and component erosion and joint space 
narrowing subscores, derived from week 0, week 24, and week 
52 images read in the second session; change from baseline in 
HAQ DI score and proportions of patients with a HAQ DI response 
(reduction ≥0.35 among patients with a baseline score ≥0.35) or 
HAQ DI score normalized to ≤0.5; resolution of enthesitis and 
changes from baseline in LEI scores in patients with enthesitis at 
baseline and resolution of dactylitis and changes from baseline in 
Dactylitis Severity Score in patients with dactylitis at baseline, both 
pooled across DISCOVER-1 and DISCOVER-2 (see Statistical 
analysis); changes from baseline in SF-36 PCS and MCS scores; 
and achievement of minimal disease activity (29) and very low dis-
ease activity (30).
Safety outcomes included AEs, serious AEs (SAEs), AEs 
resulting in discontinuation of study drug, infections, serious infec-
tions, injection-site reactions, malignancies, major adverse car-
diovascular events (MACE; predefined as cardiovascular death, 
nonfatal myocardial infarction, or nonfatal stroke), suicidal ideation 
or behavior (based on eC-SSRS questionnaire or reported AEs), 
and clinical laboratory abnormalities classified by National Can-
cer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) 
grade.
Statistical analysis. DISCOVER-2 sample size estimates 
were previously reported (19). All patients who continued treat-
ment at week 24 received guselkumab; no formal hypothesis test-
ing was planned.
As previously reported (19), treatment failure rules were 
applied to all clinical efficacy analyses through week 24, i.e., 
patients who discontinued study treatment, terminated study 
participation, initiated or increased doses of DMARDs or oral 
glucocorticoids, or initiated protocol-prohibited PsA treatment 
were considered nonresponders for binary end points, or as hav-
ing no change from baseline for continuous end points. Missing 
data were imputed as nonresponders for binary end points, and 
using multiple imputation (MI; assumed to be missing-at-random) 
for continuous end points. Radiographic data through week 24 
were imputed using MI with no treatment failure rules. The week 
24 data have been reported previously (19) and are provided 
herein as context for evaluating week 52 data.
The statistical analysis plan prespecified summarizing 
observed efficacy data from week 24 to week 52 for patients con-
tinuing study treatment after week 24 (n = 712) (Figure 1). We also 
evaluated clinical (but not radiographic) efficacy data in all treated 
patients by randomized group (n = 739) with post hoc applica-
tion of missing data imputation rules. Data missing due to treat-
ment discontinuation were considered nonresponders for binary 
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end points, or as having no change from baseline for continu-
ous end points. Data missing for other reasons were imputed as 
nonresponders for binary end points, and using MI (assumed to 
be missing-at-random) for continuous end points. In this analysis, 
data provided for the 246 patients randomized to receive placebo 
followed by guselkumab every 4 weeks included 238 patients 
who crossed over to guselkumab treatment every 4 weeks and 
8 patients who received only placebo prior to discontinuing 
Figure 1. Disposition of the patients with psoriatic arthritis (PsA) through week 52 of the DISCOVER-2 trial. CRP = C-reactive protein; 







Continuing at Week 24
236 (96%)
Screen failure: 412
 Most common reasons:
 • CRP: 272/412 (66%)
 • Exclusionary lab: 53/412 (13%)
 • Informed consent: 39/412 (9%)
 • TB criteria not met: 32/412 (8%)
Discontinued study
treatment through 
Week 24: 9 (4%)
 • Adverse events: 6
   Worsening of PsA: 0
   Other: 6
 • Inadequate efficacy: 3
Discontinued study
treatment through 
Week 24: 8 (3%)
 • Adverse events: 2
   Worsening of PsA: 0
   Other: 2
 • Inadequate efficacy: 3
 • Withdrawal of consent: 1
 • Lost to follow-up: 1
 • Other: 1
Discontinued study
treatment through 
Week 24: 6 (2%)
 • Adverse events: 4
   Worsening of PsA: 0
   Other: 4
 • Withdrawal of consent: 1
 • Other: 1
Continuing at Week 24
240 (97%)
Continuing at Week 24
240 (98%)
Continuing guselkumab
Q4W at Week 52
227 (93%)
Discontinued guselkumab
after Week 24 and prior to
Week 52: 7 (3%)
 • Adverse events: 1
   Worsening of PsA: 0
   Other: 1
 • Inadequate efficacy: 4
 • Withdrawal of consent: 1
 • Pregnancy: 1
Discontinued guselkumab
after Week 24 and prior to
Week 52: 6 (2%)
 • Inadequate efficacy: 3
 • Withdrawal of consent: 2
 • Other: 1
Discontinued guselkumab
after Week 24 and prior to
Week 52: 10 (4%)
 • Adverse events: 3
   Worsening of PsA: 1
   Other: 2
 • Inadequate efficacy: 5
 • Withdrawal of consent: 1
 • Other: 1
Discontinued before 
receiving guselkumab at
or after Week 24: 2
 • Adverse events: 1
 • Other: 1
Discontinued before 
receiving guselkumab at
or after Week 24: 2
 • Other: 2
Continuing guselkumab
Q8W at Week 52
234 (94%)
Continuing guselkumab
Q4W at Week 52
228 (93%)
Guselkumab 100 mg Q4W
n = 245
• Early escape at Week 16: 12 (5%)
Guselkumab 100 mg Q8W
n = 248
• Early escape at Week 16: 13 (5%)
Placebo
n = 246
• Early escape at Week 16: 38 (15%)
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treatment. Results based on these imputed data are the focus 
of this article; observed ACR responses are shown for reference.
Observed changes in SHS scores derived from the study’s 
second reading session were summarized via descriptive statis-
tics for patients who continued treatment at week 24 (see Sup-
plementary Figure 1, available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41553/ 
abstract). Cumulative probability plots show the observed cumu-
lative distribution of these scores, ranked from the lowest to high-
est (31), by study period (i.e., week 0 to week 24 and week 24 
to week 52). Among patients with observed scores at baseline 
and ≥1 in-window postbaseline visit, a post hoc analysis was 
conducted to estimate annual radiographic progression by ran-
domized treatment group. Further details of the analysis, which 
used linear extrapolation and MI of radiographic scores derived 
from both the first and second reading sessions, are provided in 
the Supplementary Methods.
To increase sample size and reliability, dactylitis and enthesitis 
data among patients with these conditions at baseline were pre-
specified to be summarized by pooling data across DISCOVER-1 
(18) and DISCOVER-2 (19) at week 24. Pooled results are 
also reported at week 52 (reported in the main text); individual 
DISCOVER-1 and DISCOVER-2 data are summarized in the 
 Supplementary Results, available on the Arthritis & Rheumatology 
website at http://onlinelibrary.wiley.com/doi/10.1002/art.41553/
abstract.
AEs were summarized for treated patients who experienced 
at least 1 event. To account for the shorter period of placebo (24 
weeks) compared to active treatment (52 weeks), incidences of AEs, 
SAEs, AEs leading to discontinuation of study agent, infections, and 
serious infections were also summarized as the number of patients 
or the number of events (Supplementary Methods) per 100 patient-
years of follow-up, along with corresponding exact 95% confidence 
intervals (95% CIs). Deriving from the incidences of patients with 
these AEs in the combined guselkumab and placebo groups, the 
number needed to harm (NNH), i.e., patients needing to be treated 
for an additional AE, was calculated as: R0 = 1−e
(−Placebo patients with events/
Placebo patient-years); R1 = 1−e
(−Guselkumab patients with events/Guselkumab patient-years); and 
NNH = 1/(R1 − R0). Only positive NNH values are reported.
RESULTS
Patient disposition and baseline characteristics. 
The vast majority of randomized and treated patients (689 of 
739 [93%]) completed the study through week 52; 7% of the 
patients discontinued study agent early, most commonly due to 
AEs or inadequate efficacy. The frequency of discontinuation was 
comparable across treatment groups (Figure 1). Of the patients 
who were randomized to receive placebo, 238 crossed over to 
guselkumab 100 mg every 4 weeks, and a total of 731 patients 
received guselkumab 100 mg for 608 patient-years (average 
 follow-up 43.4 weeks, or 0.8 years).
Baseline characteristics of the 739 patients in the 
 DISCOVER-2 study have been reported previously (19). 
Briefly, female (48%) and male (52%) participants had PsA for, 
on average, >5 years with no biologic treatment. At baseline, 
participants averaged 12–13 swollen and 20–22 tender joints, 
with median serum CRP levels of 1.2–1.3 mg/dl, across rand-
omized groups. Nearly three-fourths (73%) of the patients had 
≥3% BSA psoriasis involvement and an IGA score of ≥2 at week 
0, while only 2% of the patients had clear skin (IGA 0) at enroll-
ment. Approximately one-half had a psoriasis IGA score of 3–4 
(46%) or dactylitis (45%), and two-thirds had enthesitis (68%). 
Patients started the study with impaired physical function and 
HRQoL, as evidenced by their mean HAQ DI scores (1.2–1.3; 
range 0–3), mean SF-36 PCS scores (32.4–33.3), and mean 
SF-36 MCS scores (47.2–48.4) (US general population norms 
50.0). Baseline radiographic data showed an imbalance in total 
PsA-modified SHS scores between the guselkumab every 4 
weeks group and the other 2 treatment groups (Table 1).
Pharmacokinetics and immunogenicity. See Supple-
mentary Results for details on the pharmacokinetics and immu-
nogenicity of guselkumab.
Efficacy. As previously reported, the DISCOVER-2 primary 
end point was met, i.e., an ACR20 response was achieved at 
week 24 in significantly greater proportions of patients treated with 
guselkumab every 4 weeks (64%) and patients treated with gusel-
kumab every 8 weeks (64%) than patients treated with placebo 
(33%) (both P < 0.0001) (19). Numerical increases in the propor-
tions of patients in whom an ACR20 response was achieved were 
observed after week 24. By week 52, 71% of the patients ran-
domized to receive guselkumab every 4 weeks (173 of 245) and 
75% of the patients randomized to receive guselkumab every 8 
weeks (185 of 248) had ≥20% improvement from baseline in ACR 
components (Figure 2A). An ACR50 response was achieved at 
week 52 in nearly one-half, and an ACR70 response was achieved 
at week 52 in more than one-quarter of the patients randomized 
to receive guselkumab every 4 weeks or every 8 weeks (Figures 
2C and E). Consistent patterns were evident for observed ACR 
responses (Figures 2B, D, and F).
For radiographs obtained at week 0, week 24, and week 
52, intraclass correlation coefficients (ICCs) indicated good 
reader reliability for absolute scores (ICC 0.92–0.93) and moder-
ate reader reliability for change scores (ICC 0.58–0.76) (Table 1). 
The smallest detectable changes in PsA-modified SHS total 
scores were 1.85 during weeks 0–24, 1.91 during weeks 24–52, 
and 2.39 during weeks 0–52 (Supplementary Figure 1). In the 
guselkumab every 4 weeks group, observed mean changes 
in total PsA-modified SHS scores were 0.46 and 0.62 during 
weeks 0–24 and weeks 24–52, respectively. Respective mean 
changes in the guselkumab every 8 weeks group were 0.73 and 
0.23 (Table 1 and Supplementary Figure 1).
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Among patients with observed PsA-modified SHS scores at 
baseline and ≥1 in-window postbaseline visit, the least squares 
mean (LSM) change from baseline at week 52, based on a post hoc 
analysis employing linear extrapolation and MI of scores from both 
reading sessions (see Supplementary Methods), was estimated 
to be 2.16 for placebo (95% CI 1.56, 2.75). The estimated annual 
LSM changes for guselkumab every 4 weeks (1.10 [95% CI 0.48, 
1.71]) and guselkumab every 8 weeks (1.13 [95% CI 0.52, 1.73]) 
Figure 2. Proportions of patients with psoriatic arthritis who met the American College of Rheumatology criteria for 20% improvement 
(ACR20), ACR50, or ACR70 from week 24 through week 52. A, C, and E, Proportions of patients treated with guselkumab every 4 weeks 
(GUS Q4W), guselkumab every 8 weeks, or placebo (PBO) followed by guselkumab every 4 weeks who met the ACR20 (A), ACR50 (C), and 
ACR70 (E) criteria, with application of data handling rules using nonresponder imputation (NRI; see Patients and Methods). Week 24 data 
were reported previously (19) and are shown here for reference. Among 246 patients randomized to receive placebo, 238 crossed over to 
guselkumab treatment every 4 weeks (after week 24 response assessments), and 8 received placebo only before discontinuing treatment. B, 
D, and F, Observed data for the proportion of patients in each treatment group who met the ACR20 (B), ACR50 (D), and ACR70 (F) criteria. 
Observed data are shown for patients continuing study treatment at week 24, as prespecified in the statistical analysis plan.







B. ACR 20 (Observed)
Week
 GUS Q4W 234 232 230 223 228
 GUS Q8W 238 236 238 232 234























GUS Q4W, n = 245
GUS Q8W, n = 248















A. ACR 20 (NRI)







D. ACR 50 (Observed)
Week
 GUS Q4W 233 232 230 224 228
 GUS Q8W 238 237 238 234 234























GUS Q4W, n = 245
GUS Q8W, n = 248















C. ACR 50 (NRI)







F. ACR 70 (Observed)
Week
 GUS Q4W 233 232 231 225 228
 GUS Q8W 238 237 238 234 234























GUS Q4W, n = 245
GUS Q8W, n = 248















E. ACR 70 (NRI)
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yielded LSM differences from placebo of −1.06 (95% CI −1.89, 
−0.23) and −1.03 (95% CI −1.85, −0.20), respectively.
When pooling DISCOVER-1 and DISCOVER-2 patients 
with dactylitis or enthesitis at baseline, rates of resolution and 
improvements in dactylitis severity or LEI scores seen at week 24 
were maintained at week 52, at which time 75% of the patients 
who were randomized to receive guselkumab every 4 weeks or 
every 8 weeks had resolution of dactylitis and 58% had resolu-
tion of enthesitis (Table 2). Response patterns within each trial 
were consistent (Supplementary Tables 1 and 2, available on the 
Arthritis & Rheumatology website at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41553/ abstract).
In patients with ≥3% of BSA with psoriasis involvement and 
an IGA score of ≥2 at baseline, the robust skin response rates 
at week 24 afforded by guselkumab every 4 weeks and every 8 
weeks were maintained at week 52, at which time 79% and 74% 
of patients, respectively, had an IGA score of 0/1 and a ≥2-grade 
decrease from baseline, and 62% and 58%, respectively, 
achieved clear skin (IGA 0). Also at week 52, a PASI75 response 
was achieved in 86% of patients treated with guselkumab every 4 
weeks and 86% of those treated with guselkumab every 8 weeks, 
a PASI90 response was achieved in 77% of patients treated with 
guselkumab every 4 weeks and 74% of patients treated with gusel-
kumab every 8 weeks, and a PASI100 response was achieved in 
58% of patients treated with guselkumab every 4 weeks and 53% 
of patients treated with guselkumab every 8 weeks (Table 3).
Improvements in physical function seen in the guselkumab 
every 4 weeks and every 8 weeks groups at week 24 were sus-
tained through week 52 (LSM change in HAQ DI −0.49 and −0.45, 
respectively). Among patients with a baseline HAQ DI score ≥0.35 
in the guselkumab every 4 weeks and every 8 weeks groups, 
nearly 60% had improvements in HAQ DI ≥0.35 at week 52. Also 
by week 52, 33% and 25% of the patients in the guselkumab 
every 4 weeks and every 8 weeks groups, respectively, with a 
HAQ DI ≥0.5 at baseline saw normalized physical function, i.e., 
HAQ DI <0.5. Consistently, guselkumab every 4 weeks or every 
8 weeks continued to numerically improve physical aspects of 
HRQoL through week 52, at which time LSM changes in SF-36 
PCS score were 8.6 and 9.0, respectively. The LSM improve-
ments in mental components of HRQoL were maintained through 
week 52 (SF-36 MCS score 4.4 and 4.3, respectively) (Table 3).
Utilizing validated PsA composite indices, minimal disease 
activity was achieved in >30% of the patients in the guselkumab 
every 4 weeks and guselkumab every 8 weeks groups, and very 
low disease activity was achieved in 11% and 16% of the patients 
in the guselkumab every 4 weeks and every 8 weeks groups, 
respectively, at week 52 (Table 3).
In patients who received guselkumab every 4 weeks from 
week 24 to week 52 following treatment with placebo, clinical 
response rates at week 52 (e.g., ACR20 in 64%, IGA score of 0/1 
in 79%, HAQ DI response in 48%, and minimal disease activity 
in 30%) were consistent with those observed in patients ran-
domized to receive guselkumab (Tables 2 and 3 and Figure 2). Also 
in patients who crossed over from placebo to guselkumab every 
4 weeks, mean changes in total PsA-modified SHS scores were 
1.00 from week 0 to week 24 and 0.25 from week 24 to week 52 
(Table 1 and Supplementary Figure 1).
Safety. Consistent with findings through week 24 of 
DISCOVER-2 (19), the most commonly reported AEs (>5% of 
patients in any guselkumab treatment group) through week 52 
included upper respiratory tract infection (7% of patients ran domized 
to treatment every 4 weeks, 7% of patients randomized to treatment 
every 8 weeks, and 10 per 100 patient-years for all guselkumab-  
treated patients), nasopharyngitis (7%, 8%, and 9 per 100 
patient-years, respectively), bronchitis (6%, 2%, and 4 per 100 
Table 2. Pooled DISCOVER-1 and DISCOVER-2 dactylitis and enthesitis data through week 52*
Guselkumab every 4 weeks  
(n = 373)†
Guselkumab every 8 weeks  
(n = 375)†
Placebo (weeks 0–24) → 
guselkumab every 4 weeks  
(weeks 24–52)  
(n = 372)†§
Week 24‡ Week 52 Week 24‡ Week 52 Week 24‡ Week 52
No. with dactylitis at week 0 159 159 160 160 154¶ 154
% with resolution 63.5 74.8 59.4 75.6 42.2 70.1
LSM change (95% CI) −6.0 (−6.8, −5.1) −6.5 (−7.1, −5.8) −6.1 (−6.9, −5.3) −7.1 (−7.8, −6.5) −4.2 (−5.0, −3.4) −6.6 (−7.3, −5.9)
No. with enthesitis at week 0 243 243 230 230 255# 255
% with resolution 44.9 57.6 49.6 57.8 29.4 61.6
LSM change (95% CI) −1.6 (−1.8, −1.4) −1.8 (−2.0, −1.6) −1.5 (−1.7, −1.3) −1.8 (−2.0, −1.6) −1.0 (−1.2, −0.8) −1.8 (−2.0, −1.7)
* Data are summarized by treatment group with application of missing data handling rules (see Patients and Methods). LSM = least squares 
mean; 95% CI = 95% confidence interval. 
† Numbers of pooled randomized patients. 
‡ Week 24 data were previously reported (19) and are shown here for reference. 
§ Of these 372 patients, 352 crossed over to guselkumab treatment every 4 weeks (post–week 24 response assessments); 20 received placebo 
only before discontinuing treatment. 
¶ Of these 154 patients, 142 crossed over to guselkumab treatment every 4 weeks (post–week 24 response assessments); 12 received placebo 
only before discontinuing treatment. 
# Of these 255 patients, 243 crossed over to guselkumab treatment every 4 weeks (post–week 24 response assessments); 12 received placebo 
only before discontinuing treatment. 
McINNES ET AL 612       |
patient-years, respectively), and investigator-reported laboratory 
investigations, including increased alanine aminotransferase (ALT) 
level (12%, 9%, and 13 per 100 patient-years, respectively) and 
increased aspartate aminotransferase (AST) level (7%, 7%, and 
5 per 100 patient-years, respectively). When evaluating AEs with 
>5 events per 100 patient-years in any group, common AEs also 
included neutropenia and leukopenia (Supplementary Table 3, 
available on the Arthritis & Rheumatology website at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41553/ abstract). Across all AEs, 
time-adjusted incidences were 109 and 110 per 100 patient-
years during weeks 0–52 for patients receiving guselkumab every 
4 weeks or every 8 weeks, respectively (Table 4).
No deaths occurred through week 52. Overall, 4% of 
 guselkumab-treated patients (31 of 731) had SAEs, with similar 
proportions observed in the guselkumab every 4 weeks and every 
8 weeks groups (Table 4). Eighteen (58%) of 31 guselkumab- 
treated patients with SAEs were receiving methotrexate, 1 (3%) re-
ceived leflunomide, and 12 (39%) did not receive any non biologic 
DMARDs. Lower limb fracture, goiter, pneumonia (1 identified 
as influenzal in origin), and pulmonary embolism each occurred in 
2 guselkumab-treated patients. Other SAEs were singular events. 
One patient each with serious influenza/pneumonia, ischemic 
stroke, and acute hepatitis B in the guselkumab every 4 weeks 
group discontinued treatment. Most SAEs in guselkumab-treated 
patients resolved by week 52. Exceptions were extrapyramidal 
disorder, endometrial hyperplasia, and acute hepatitis B, each in 
1 patient who received guselkumab every 4 weeks during weeks 
0–52.
Guselkumab and placebo were each discontinued due to 
AEs by ~2% of patients. Nine guselkumab-treated patients (NNH 
164) and 1 placebo-treated patient had serious infections through 
week 52. Serious infections were reported by similar proportions 
of patients receiving guselkumab every 4 weeks (1%) and those 
receiving guselkumab every 8 weeks (1%) during weeks 0–52, 
and by similar proportions of the 493 guselkumab-randomized 
patients during weeks 0–24 (4 patients [0.8%]) (19) and weeks 
24–52 (3 patients [0.6%]) (Table 4). No patient had active tubercu-
losis (TB) or an opportunistic infection through week 52. Among 
Table 3. Summary of skin, patient-reported, and composite end point outcomes through week 52 of the DISCOVER-2 trial*
Guselkumab every 4 weeks Guselkumab every 8 weeks
Placebo (weeks 0–24) → 
guselkumab every 4 weeks 
(weeks 24–52)
Week 24† Week 52 Week 24† Week 52 Week 24† Week 52
No. with ≥3% BSA psoriasis and IGA 
≥2 at week 0
184 184 176 176 183‡ 183‡
IGA score of 0/1 and ≥2-grade 
decrease
68.5 79.3 70.5 74.4 19.1 79.2
IGA score of 0 50.5 62.5 50.0 58.0 7.7 62.8
PASI75 78.3 86.4 79.0 85.8 23.0 83.1
PASI90 60.9 76.6 68.8 74.4 9.8 72.1
PASI100 44.6 57.6 45.5 52.8 2.7 51.9
No. with HAQ DI available 245 245 248 248 246§ 246§












No. with HAQ DI ≥0.5 at week 0 225 225 221 221 227 227
HAQ DI <0.5 25.8 32.9 20.8 25.3 12.3 24.7
No. with HAQ DI ≥0.35 at week 0 228 228 228 228 236¶ 236¶
≥0.35 improvement 56.1 58.8 50.0 57.5 31.4 47.5
No. with SF-36 scores available 245 245 248 248 246§ 246§
























No. with data on composite indices 
available
245 245 248 248 246§ 246§
Minimal disease activity 18.8 34.3 25.0 31.0 6.1 29.7
Very low disease activity 4.9 11.4 4.4 16.1 1.2 6.5
* Data are summarized by treatment group with application of missing data handling rules (see Patients and Methods). Except where indicated 
otherwise, values are the percent of patients. BSA = body surface area; IGA = Investigator’s Global Assessment of psoriasis; PASI75 = ≥75% 
improvement in the Psoriasis Area and Severity Index; HAQ DI = Health Assessment Questionnaire disability index; LSM = least squares mean; 
95% CI = 95% confidence interval; SF-36 = Short Form 36; PCS = physical component summary; MCS = mental component summary. 
† Week 24 data were previously reported (19) and are shown here for reference. 
‡ Of these 183 patients, 176 crossed over to guselkumab treatment every 4 weeks (post–week 24 response assessments); 7 received placebo 
only before discontinuing treatment. 
§ Of these 246 patients, 238 crossed over to guselkumab treatment every 4 weeks (post–week 24 response assessments); 8 received placebo 
only before discontinuing treatment. 
¶ Of these 236 patients, 229 crossed over to guselkumab treatment every 4 weeks (post–week 24 response assessments); 7 received placebo 
only before discontinuing treatment. 
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75 patients (10%) who were required to start treatment for latent 
TB prior to the first study agent administration, 2 (1 receiving pla-
cebo and 1 receiving guselkumab every 4 weeks [see below]) 
were reported to have isoniazid-induced liver injury. No AEs of 
inflammatory bowel disease were reported in guselkumab-treated 
patients.
No malignancies were reported during weeks 24–52, while 2 
were reported during weeks 0–24 (melanoma in situ in the gusel-
kumab every 8 weeks group and renal clear cell cancer in the 
placebo group) (19). No MACE occurred during weeks 24–52; 1 
event (ischemic stroke in the guselkumab every 4 weeks group) 
was reported prior to week 24 (19).
One patient, who received guselkumab every 8 weeks, 
reported suicidal ideation during weeks 24–52; 2 patients (1 each 
in the placebo and guselkumab every 4 weeks groups) did so 
during weeks 0–24 (19). No events of self-injurious or suicidal 
behavior were reported through week 52. Injection-site reactions 
related to guselkumab injections occurred in 1.4% of guselkum-
ab-treated patients (10 of 731) through week 52 (see Supplemen-
tary Results).
Through week 52, decreased neutrophil counts of NCI 
CTCAE grade 2 or higher (<1.5 × 109/liter) were infrequent, occur-
ring in 3.7% of patients (9 of 243) who received guselkumab 
every 4 weeks from week 0 and 3.6% of patients (9 of 247) who 
Table 4. Patients with AE categories of interest through week 52 of the DISCOVER-2 trial*
Placebo → guselkumab 100 mg  
every 4 weeks












No. of treated patients 246 238† 245 248 731
Years of follow-up, mean 0.5 0.5 1.0 1.0 0.8
Overall patient-years, no. 115 127 239 243 608
All AEs
Patient-years, no. 86 102 140 140 383
Number (%) of patients 100 (40.7) 87 (36.6) 152 (62.0)‡ 155 (62.5)‡ 394 (53.9)











Patient-years, no. 113 124 233 238 595
Number (%) of patients 7 (2.8) 10 (4.2) 11 (4.5)§ 10 (4.0)§ 31 (4.2)










AEs causing study agent discontinuation
Patient-years, no. 114 127 236 242 605
Number (%) of patients 4 (1.6) 4 (1.7) 9 (3.7)¶ 3 (1.2)¶ 16 (2.2)











Patient-years, no. 104 116 197 204 516
Number (%) of patients 45 (18.3) 41 (17.2) 67 (27.3)# 71 (28.6)# 179 (24.5)











Patient-years, no. 115 126 237 241 605
Number (%) of patients 1 (0.4)** 3 (1.3)†† 3 (1.2)‡‡ 3 (1.2)§§ 9 (1.2)










* 95% CI = 95% confidence interval; SAEs = serious adverse events. 
† These 238 patients received placebo during weeks 0–24; only adverse events reported during weeks 24–52, after starting guselkumab, 
are summarized. 
‡ One hundred thirteen (46.1%) of the patients receiving guselkumab 100 mg every 4 weeks and 114 (46.0%) of the patients receiving 
guselkumab 100 mg every 8 weeks reported AEs during weeks 0–24 (19). 
§ Eight (3.3%) of the patients receiving guselkumab 100 mg every 4 weeks and 3 (1.2%) of the patients receiving guselkumab 100 mg every 
8 weeks reported SAEs during weeks 0–24 (19). 
¶ Seven (2.9%) of the patients receiving guselkumab 100 mg every 4 weeks and 2 (0.8%) of the patients receiving guselkumab 100 mg 
every 8 weeks discontinued study agent due to AEs during weeks 0–24 (19). 
# Forty-nine (20.0%) of the patients receiving guselkumab 100 mg every 4 weeks and 40 (16.1%) of the patients receiving guselkumab 
100 mg every 8 weeks reported infections during weeks 0–24 (19). 
** Post-procedural fistula while receiving placebo prior to week 24 (19). 
†† One patient each with influenza/tracheitis, pericarditis, and pneumonia while receiving guselkumab 100 mg every 4 weeks during 
weeks 24–52. 
‡‡ One patient each with acute hepatitis B, oophoritis, and influenzal pneumonia prior to week 24 (19). 
§§ One patient had pyrexia prior to week 24 (19) and urinary tract infection during weeks 24–52, and 1 patient each had cystitis and 
diverticulitis during weeks 24–52. 
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received guselkumab every 8 weeks from week 0. Fewer than 1% 
of guselkumab-treated patients (5 of 731) had decreased neutro-
phil counts of grade 3 or higher, including 4 with grade 3 values 
(<1.0–0.5 × 109/liter) and 1 with grade 4 values (<0.5 × 109/liter). 
These findings were generally transient and reversible, resolved 
spontaneously without treatment, and did not require discontinu-
ation of study agent. No associated infections were seen, except 
a case of mild nasopharyngitis temporally associated with grade 
2 neutropenia. Decreased white blood cell counts of NCI CTCAE 
grade 2 (<3.0–2.0 × 109/liter) occurred in 2.1% of patients (5 of 
243) who received guselkumab every 4 weeks from week 0 and 
2.4% of patients (6 of 247) who received guselkumab every 8 
weeks from week 0; no guselkumab-treated patient exhibited leu-
kopenia of grade 3 or 4 (>2.0 × 109/liter) (Supplementary Table 4, 
available on the Arthritis & Rheumatology website at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41553/ abstract).
Through week 52, elevated ALT and/or AST concentrations 
of NCI CTCAE grade 2 or higher (>3 times the upper limit of normal 
[ULN]) occurred in 7.4% and 6.6%, respectively, of 243 patients 
receiving guselkumab every 4 weeks from week 0 and 2.0% and 
3.2%, respectively, of 247 patients receiving guselkumab every 
8 weeks from week 0. No additional grade 3 ALT or AST values 
(>5–20 times the ULN), which were uncommon during weeks 0–24 
(1.4% and 1.2%, respectively, of 493 guselkumab-randomized 
patients) (19), occurred after week 24. No grade 4 ALT or AST val-
ues (>20 times the ULN) occurred through week 52 (Supplemen-
tary Table 4). No instance of elevated liver function test findings 
satisfied the criteria for Hy’s Law (total bilirubin >2 times the ULN 
and ALT or AST ≥3 times the ULN) among guselkumab-treated 
patients. Most abnormal findings were transient, resolved, and 
did not require discontinuation of study agent. As exceptions and 
as reported previously, 2 patients randomized to receive gusel-
kumab every 4 weeks discontinued guselkumab prior to week 24 
(1 each with acute hepatitis B and isoniazid-induced liver injury) 
(19). Another patient, in the guselkumab every 4 weeks group, 
had an extended interruption of treatment before week 24 (owing 
to physician concerns surrounding alcohol use, hepatic steatosis, 
and chronic cholecystitis with persistently elevated transaminase 
levels [AST dominant]). One patient who switched from placebo to 
guselkumab every 4 weeks, with nonalcoholic fatty liver disease, 
had a grade 1 ALT elevation (>1–3 times the ULN) at week 52 and 
discontinued guselkumab after week 52. Increased ALT and AST 
concentrations occurred in 26% and 25%, respectively, of 436 
guselkumab-treated patients receiving methotrexate, and in 24% 
and 20%, respectively, of 292 such patients not receiving metho-
trexate, at baseline.
Total bilirubin elevations in guselkumab-treated patients were 
either grade 1 (>1–1.5 times the ULN; 5% of all guselkumab- 
treated patients) or grade 2 (>1.5–3 times the ULN; 1% of all 
guselkumab-treated patients) (Supplementary Table 4). All such 
elevations were <2 times the ULN and not associated with direct 
bilirubin elevation.
DISCUSSION
Through week 52 of DISCOVER-2, a pivotal phase III gusel-
kumab trial that enrolled biologic-naive PsA patients with extensive 
disease activity despite standard treatments, guselkumab 100 mg 
every 4 weeks and every 8 weeks provided clinically meaningful 
and sustained benefits to participants. The significant improve-
ments in arthritis symptoms, psoriatic lesions, dactylitis and 
enthesitis, physical function, and physical components of HRQoL 
achieved at week 24 of DISCOVER-2 (19) were maintained at 
week 52. Further, numerical improvements seen through week 52 
suggested that a further 6 months of guselkumab 100 mg every 
4 weeks or every 8 weeks may provide added benefit across 
response measures. In placebo-treated patients who initiated 
guselkumab every 4 weeks at week 24, the onset and magnitude 
of the guselkumab effect confirmed initial observations in patients 
receiving guselkumab every 4 weeks from week 0 to week 24.
Structural joint damage, exhibited by nearly half of PsA 
patients within 2 years of symptom onset, often progresses to 
irreversible damage and disability (32). Understandably, inhibiting 
structural damage progression is a key PsA treatment goal (2,3). 
The guselkumab every 4 weeks regimen significantly inhibited 
structural damage progression, as measured by mean changes 
in total PsA-modified SHS scores, during weeks 0–24 (19). At the 
group level, limited radiographic progression was also observed 
during weeks 24–52 in patients who continued guselkumab every 
4 weeks or every 8 weeks and in patients who initiated gusel-
kumab every 4 weeks at week 24. Mean changes in PsA- 
modified SHS scores during weeks 0–52 were numerically similar 
for the guselkumab every 4 weeks and every 8 weeks regimens. 
It should be noted, however, that the average PsA-modified SHS 
score at baseline was numerically higher in the guselkumab every 
4 weeks group, and a higher baseline radiographic score is a 
known risk factor for further radiographic progression (33). Over-
all, minimal radiographic progression was seen in the vast major-
ity of patients, while only a few patients in each treatment group 
exhibited clinically meaningful progression of structural damage, 
through 1 year.
PsA is a complex, clinically diverse, chronic inflammatory 
disorder driven by excess IL-23/Th-17–mediated cytokines. The 
ability of selective IL-23 inhibition with guselkumab to sustain 
improvements in disparate areas of disease through up to 1 year is 
encouraging in a disorder that can recur after loss of initial response 
and that can be recalcitrant to biologics (1,34). Further, given the 
growing consensus surrounding the ultimate goal of PsA therapy 
and treatment-to-target, i.e., absence of symptoms for those with 
early disease or limited joint damage or low levels of disease activity 
for patients presenting with established disease and/or irreversible 
damage (35), minimal disease activity responses at week 52 sug-
gest that treatment target was achieved in nearly one-third of these 
guselkumab-treated patients, who were biologic-naive and on 
average had PsA for >5 years at study outset. Thus, guselkumab 
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was shown to offer a novel mechanism, i.e., binding to the p19 
subunit of IL-23 but not the p40 subunit it shares with IL-12, to tar-
get the key upstream regulatory cytokine implicated in PsA patho-
genesis and elicit sustained clinical response.
Importantly, the favorable risk–benefit profile observed 
through week 24 (19) was supported by findings through week 
52, representing a total of 608 patient-years of follow-up. Rela-
tive to previously reported data through week 24 of DISCOVER-2 
(19), no increase in the incidence of serious infections occurred 
with continued guselkumab every 4 weeks or every 8 weeks. No 
patient had active TB or an opportunistic infection, and no deaths 
occurred, through week 52. No additional malignancies or MACE 
occurred after week 24, and inflammatory bowel disease was not 
reported in any patient while receiving guselkumab.
Interpretation of findings through 1 year of DISCOVER-2 is 
hampered by a shorter duration of placebo than active treat-
ment. To address this, we estimated numbers of patients with 
AEs per 100 patient-years assuming a constant incidence over 
time, a customary approach to standardize AE data for com-
parative purposes. Further, because interpretation of observed 
efficacy data from clinical trial extensions can also be con-
founded by enriching the long-term data set with responders, 
we conservatively summarized clinical efficacy responses by 
imputing data missing due to discontinued treatment as non-
response or no change from baseline. Joint counts were not 
adjusted for the presence of dactylitis in the same digit, as these 
disease domains were independently assessed. However, as 
ACR response rates were consistent in patients with or without 
dactylitis at baseline (data not shown), we do not anticipate any 
impact on study conclusions. One year is a limited period for 
assessing patient retention and safety, as well as the structural 
damage and disability that trail extended periods of untreated 
systemic inflammation in this chronic condition. Data obtained 
during the second year of DISCOVER-2 will augment current 
knowledge of the guselkumab risk–benefit profile and further our 
understanding of longer-term radiographic outcomes with both 
guselkumab dosing regimens.
In conclusion, guselkumab 100 mg every 4 weeks or every 8 
weeks effectively treated the diverse manifestations of active PsA 
in biologic-naive patients. The overall treatment effect observed 
during the 24-week placebo-controlled period was well main-
tained, and the risk–benefit profile remained favorable for both 
guselkumab regimens, through week 52 of DISCOVER-2.
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